Padcev – Talk Bio

Actionable Insights Powered by AI

Phase III Study: Perioperative Padcev & Keytruda Combo Significantly Improves Survival in Bladder Cancer

4 weeks ago talkbio0Tagged cisplatin-ineligible, enfortumab, Event-Free Survival, Keytruda, Malignant neoplasm of urinary bladder, muscle-invasive bladder cancer, Overall Survival, Padcev, pembrolizumab, perioperative, Phase III, vedotin

Padcev; Keytruda; enfortumab vedotin; pembrolizumab; phase III; bladder cancer; muscle-invasive bladder cancer; cisplatin-ineligible; perioperative; event-free survival; overall survival

Corbus’ Nectin-4 ADC Shows Promise in Western Study, Challenging Pfizer’s Padcev

7 months ago talkbio0Tagged Antibody-Drug Conjugates, ASCO-GU, Cancer of Neck, Clinical Trials, Corbus Pharmaceuticals, CRB-701, NECTIN4 gene, Padcev, urothelial cancer

Corbus Pharmaceuticals, CRB-701, antibody-drug conjugate, Nectin-4, urothelial cancer, head and neck cancer, Padcev, clinical trial, ASCO-GU 2025